LifeTime and improving European healthcare through cell-based interceptive medicine.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Rajewsky, NikolausAlmouzni, Geneviève
Gorski, Stanislaw A
Aerts, Stein
Amit, Ido
Bertero, Michela G
Bock, Christoph
Bredenoord, Annelien L
Cavalli, Giacomo
Chiocca, Susanna
Clevers, Hans
De Strooper, Bart
Eggert, Angelika
Ellenberg, Jan
Fernández, Xosé M
Figlerowicz, Marek
Gasser, Susan M
Hubner, Norbert
Kjems, Jørgen
Knoblich, Jürgen A
Krabbe, Grietje
Lichter, Peter
Linnarsson, Sten
Marine, Jean-Christophe
Marioni, John
Marti-Renom, Marc A
Netea, Mihai G
Nickel, Dörthe
Nollmann, Marcelo
Novak, Halina R
Parkinson, Helen
Piccolo, Stefano
Pinheiro, Inês
Pombo, Ana
Popp, Christian
Reik, Wolf
Roman-Roman, Sergio
Rosenstiel, Philip
Schultze, Joachim L
Stegle, Oliver
Tanay, Amos
Testa, Giuseppe
Thanos, Dimitris
Theis, Fabian J
Torres-Padilla, Maria-Elena
Valencia, Alfonso
Vallot, Céline
van Oudenaarden, Alexander
Vidal, Marie
Voet, Thierry
Issue Date
2020-09-07
Metadata
Show full item recordAbstract
LifeTime aims to track, understand and target human cells during the onset and progression of complex diseases and their response to therapy at single-cell resolution. This mission will be implemented through the development and integration of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during progression from health to disease. Analysis of such large molecular and clinical datasets will discover molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. Timely detection and interception of disease embedded in an ethical and patient-centered vision will be achieved through interactions across academia, hospitals, patient-associations, health data management systems and industry. Applying this strategy to key medical challenges in cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.Citation
Nature. 2020 Sep 7. doi: 10.1038/s41586-020-2715-9. Epub ahead of print.Affiliation
TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.Publisher
Nature publishing group(NPG)Journal
NaturePubMed ID
32894860Type
ArticleOther
Language
enEISSN
1476-4687ae974a485f413a2113503eed53cd6c53
10.1038/s41586-020-2715-9
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Suicidal Ideation
- Authors: Harmer B, Lee S, Duong TvH, Saadabadi A
- Issue date: 2020 Jan
- The future of Cochrane Neonatal.
- Authors: Soll RF, Ovelman C, McGuire W
- Issue date: 2020 Nov
- Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification
- Authors: Wolahan SM, Hirt D, Glenn TC, Kobeissy FH
- Issue date: 2015
- Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
- Authors: Hafner J
- Issue date: 2008 Feb 13
- Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.
- Authors: Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, Mol P, Naci H, Samani NJ, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski A, Kirchhof P
- Issue date: 2016 Mar 1